Novartis AG annual depreciation and amortization
2021
2022
2023
2024
2025
Novartis AG Depreciation & Amortization Growth & History (NVS)
Novartis AG's depreciation and amortization was $951.0M for fiscal 2025.
View full Novartis AG company overviewNovartis AG annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $951.0M | $66.0M | +7.46% |
| 2024 | 2024-12-31 | $885.0M | −$7.39B | −89.31% |
| 2023 | 2023-12-31 | $8.28B | $7.11B | +611.69% |
| 2022 | 2022-12-31 | $1.16B | −$45.0M | −3.73% |
| 2021 | 2021-12-31 | $1.21B | — | — |
Novartis AG quarterly depreciation and amortization
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.40B | $144.0M | +11.46% |
| Q1 2026 | 2026-03-31 | $1.23B | — | — |
| Q4 2025 | 2025-12-31 | $1.55B | — | — |
| Q3 2025 | 2025-09-30 | $1.36B | — | — |
| Q2 2025 | 2025-06-30 | $1.26B | — | — |
Novartis AG depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, Novartis AG's depreciation and amortization decreased from $1.21B to $951.0M, a change of −$257.0M. The latest reported quarter, Q2 2026, shows $1.40B.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...